Global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is predicted to grow from US$ 6394 million in 2025 to US$ 31580 million in 2031; it is expected to grow at a CAGR of 30.5% from 2025 to 2031. Get Access Now!

Global Chimeric Antigen Receptor CAR T-Cell Therapy Market Growth Status and Outlook 2025-2031

The global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size is predicted to grow from US$ 6394 million in 2025 to US$ 31580 million in 2031; it is expected to grow at a CAGR of 30.5% from 2025 to 2031. Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer. The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patients T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients. LPI (LP Information) newest research report, the Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Forecast looks at past sales and reviews total world Chimeric Antigen Receptor (CAR) T-Cell Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor (CAR) T-Cell Therapy sales for 2025 through 2031. With Chimeric Antigen Receptor (CAR) T-Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor (CAR) T-Cell Therapy industry. This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor (CAR) T-Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chimeric Antigen Receptor (CAR) T-Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor (CAR) T-Cell Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor (CAR) T-Cell Therapy. This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor (CAR) T-Cell Therapy market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; CD19-targeted &nbsp;&nbsp;&nbsp; BCMA-targeted Segmentation by Application: &nbsp;&nbsp;&nbsp; Lymphoma &nbsp;&nbsp;&nbsp; Multiple Myeloma This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Gilead Sciences &nbsp;&nbsp;&nbsp; Bristol-Myers Squibb &nbsp;&nbsp;&nbsp; J & J &nbsp;&nbsp;&nbsp; JW Therapeutics &nbsp;&nbsp;&nbsp; FOSUNKite &nbsp;&nbsp;&nbsp; CARsgen Therapeutics &nbsp;&nbsp;&nbsp; Autolus Therapeutics &nbsp;&nbsp;&nbsp; Sorrento Therapeutics &nbsp;&nbsp;&nbsp; Mustang Bio &nbsp;&nbsp;&nbsp; Bluebird Bio &nbsp;&nbsp;&nbsp; Cellectis &nbsp;&nbsp;&nbsp; Allogene Therapeutics &nbsp;&nbsp;&nbsp; Celyad

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size (2020-2031) &nbsp;2.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Chimeric Antigen Receptor (CAR) T-Cell Therapy by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Type &nbsp;2.2.1 CD19-targeted &nbsp;2.2.2 BCMA-targeted &nbsp;2.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type &nbsp;2.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Type (2020-2025) &nbsp;2.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment by Application &nbsp;2.4.1 Lymphoma &nbsp;2.4.2 Multiple Myeloma &nbsp;2.5 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application &nbsp;2.5.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Application (2020-2025) 3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Player &nbsp;3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Market Share by Player &nbsp;3.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue by Player (2020-2025) &nbsp;3.1.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Chimeric Antigen Receptor (CAR) T-Cell Therapy by Region &nbsp;4.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (2020-2025) &nbsp;4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Growth (2020-2025) &nbsp;4.4 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Growth (2020-2025) &nbsp;4.5 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2020-2025) &nbsp;5.2 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2020-2025) &nbsp;5.3 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region (2020-2025) &nbsp;6.2 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2020-2025) &nbsp;6.3 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country (2020-2025) &nbsp;7.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2020-2025) &nbsp;7.3 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy by Region (2020-2025) &nbsp;8.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast &nbsp;10.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Region (2026-2031) &nbsp;10.1.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.1.3 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.1.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.1.5 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.2 Americas Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.2.2 Canada Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.2.3 Mexico Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.2.4 Brazil Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.3 APAC Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Region (2026-2031) &nbsp;10.3.1 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast &nbsp;10.3.2 Japan Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.3.3 Korea Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.3.4 Southeast Asia Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.3.5 India Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.3.6 Australia Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.4.2 France Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.4.3 UK Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.4.4 Italy Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.4.5 Russia Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.5 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.5.2 South Africa Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.5.3 Israel Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.5.4 Turkey Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast &nbsp;10.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Type (2026-2031) &nbsp;10.7 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Forecast 11 Key Players Analysis &nbsp;11.1 Novartis &nbsp;11.1.1 Novartis Company Information &nbsp;11.1.2 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.1.3 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Novartis Main Business Overview &nbsp;11.1.5 Novartis Latest Developments &nbsp;11.2 Gilead Sciences &nbsp;11.2.1 Gilead Sciences Company Information &nbsp;11.2.2 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.2.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Gilead Sciences Main Business Overview &nbsp;11.2.5 Gilead Sciences Latest Developments &nbsp;11.3 Bristol-Myers Squibb &nbsp;11.3.1 Bristol-Myers Squibb Company Information &nbsp;11.3.2 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.3.3 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Bristol-Myers Squibb Main Business Overview &nbsp;11.3.5 Bristol-Myers Squibb Latest Developments &nbsp;11.4 J & J &nbsp;11.4.1 J & J Company Information &nbsp;11.4.2 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.4.3 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 J & J Main Business Overview &nbsp;11.4.5 J & J Latest Developments &nbsp;11.5 JW Therapeutics &nbsp;11.5.1 JW Therapeutics Company Information &nbsp;11.5.2 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.5.3 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 JW Therapeutics Main Business Overview &nbsp;11.5.5 JW Therapeutics Latest Developments &nbsp;11.6 FOSUNKite &nbsp;11.6.1 FOSUNKite Company Information &nbsp;11.6.2 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.6.3 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 FOSUNKite Main Business Overview &nbsp;11.6.5 FOSUNKite Latest Developments &nbsp;11.7 CARsgen Therapeutics &nbsp;11.7.1 CARsgen Therapeutics Company Information &nbsp;11.7.2 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.7.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 CARsgen Therapeutics Main Business Overview &nbsp;11.7.5 CARsgen Therapeutics Latest Developments &nbsp;11.8 Autolus Therapeutics &nbsp;11.8.1 Autolus Therapeutics Company Information &nbsp;11.8.2 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.8.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Autolus Therapeutics Main Business Overview &nbsp;11.8.5 Autolus Therapeutics Latest Developments &nbsp;11.9 Sorrento Therapeutics &nbsp;11.9.1 Sorrento Therapeutics Company Information &nbsp;11.9.2 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.9.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Sorrento Therapeutics Main Business Overview &nbsp;11.9.5 Sorrento Therapeutics Latest Developments &nbsp;11.10 Mustang Bio &nbsp;11.10.1 Mustang Bio Company Information &nbsp;11.10.2 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.10.3 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Mustang Bio Main Business Overview &nbsp;11.10.5 Mustang Bio Latest Developments &nbsp;11.11 Bluebird Bio &nbsp;11.11.1 Bluebird Bio Company Information &nbsp;11.11.2 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.11.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Bluebird Bio Main Business Overview &nbsp;11.11.5 Bluebird Bio Latest Developments &nbsp;11.12 Cellectis &nbsp;11.12.1 Cellectis Company Information &nbsp;11.12.2 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.12.3 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Cellectis Main Business Overview &nbsp;11.12.5 Cellectis Latest Developments &nbsp;11.13 Allogene Therapeutics &nbsp;11.13.1 Allogene Therapeutics Company Information &nbsp;11.13.2 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.13.3 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 Allogene Therapeutics Main Business Overview &nbsp;11.13.5 Allogene Therapeutics Latest Developments &nbsp;11.14 Celyad &nbsp;11.14.1 Celyad Company Information &nbsp;11.14.2 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product Offered &nbsp;11.14.3 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Celyad Main Business Overview &nbsp;11.14.5 Celyad Latest Developments 12 Research Findings and Conclusion

Report	Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI35830

Buyer Information

Order Summary